President, Chief Executive Officer, & Director
Joining the board in 2020, Kim Murphy possesses a wealth of vaccine industry knowledge and experience that was vital to the company’s strategic acquisition of Noachis Terra, as well as the development of Oragenics’ other product candidates. Ms. Murphy served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (GSK). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Earlier in her career, she worked in commercialization roles within Merck and Novartis Vaccines and Diagnostics Inc. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV). Ms. Murphy holds a B.A. in English from Old Dominion University and an MBA in Marketing from Saint Joseph’s University.
Martin (Marty) Handfield, PhD
Chief Scientific Officer (CSO)
Dr. Handfield is Oragenics’ Chief Scientific Officer and has previously served as our Senior Vice President of Discovery Research and as our Director of Research and Development. Prior to joining the company in 2009, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded iviGene Corporation and Epicure Corporation. Dr. Handfield is the recipient of 5 classes of patents and co-authored over 50 publications and book chapters, with a focus on infectious diseases, antibiotic development, transcriptomics, proteomics and molecular microbiology. His research generated over 10 million dollars from diverse funding agencies. His current work at Oragenics is funded by a SBIR grant awarded from the National Institute of General Medical Sciences (NIGMS) at the National Institutes of Health (NIH).
Dr. Handfield holds a BS in Biochemistry and an MS and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada. He completed postdoctoral training at the University of Florida under the mentorship of Dr. Jeffrey Hillman, Oragenics’ Founder and CSO (Ret.).
Chief Financial Officer
Ms. Huffman served as Chief Financial Officer for TRxADE HEALTH, Inc., a Nasdaq-listed company focused on health services IT for retail pharmacies. In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer. After leading Banyan’s merger with Assisted 4 Living, Inc., an OTC-listed company later renamed Arboreta Healthcare Inc. and a provider of skilled nursing, rehabilitation and assisted living services, she continued as Chief Financial Officer until February 2022. Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company. Earlier in her career, she served as Director of Finance and Regional Director of Operations for Infinity Homecare and was Vice President of Finance for Family Home Health Services.
Ms. Huffman obtained a Bachelor’s degree in accounting and a Master’s degree in accounting, both from the University of South Florida.